Triasima Portfolio Management inc. Trims Position in Boston Scientific Corporation $BSX

Triasima Portfolio Management inc. lessened its stake in shares of Boston Scientific Corporation (NYSE:BSX) by 92.8% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 3,495 shares of the medical equipment provider’s stock after selling 45,169 shares during the period. Triasima Portfolio Management inc.’s holdings in Boston Scientific were worth $333,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also modified their holdings of the company. FWL Investment Management LLC purchased a new position in shares of Boston Scientific during the 2nd quarter worth $26,000. Murphy & Mullick Capital Management Corp raised its holdings in shares of Boston Scientific by 200.0% during the 3rd quarter. Murphy & Mullick Capital Management Corp now owns 255 shares of the medical equipment provider’s stock worth $25,000 after acquiring an additional 170 shares during the period. Financial Consulate Inc. purchased a new stake in Boston Scientific in the 3rd quarter valued at about $25,000. United Community Bank raised its holdings in Boston Scientific by 115.7% in the 3rd quarter. United Community Bank now owns 274 shares of the medical equipment provider’s stock valued at $27,000 after buying an additional 147 shares during the period. Finally, Colonial Trust Co SC raised its holdings in Boston Scientific by 502.2% in the 3rd quarter. Colonial Trust Co SC now owns 277 shares of the medical equipment provider’s stock valued at $27,000 after buying an additional 231 shares during the period. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on the stock. Daiwa Securities Group lowered shares of Boston Scientific from a “strong-buy” rating to a “hold” rating in a report on Wednesday, April 29th. Stifel Nicolaus reduced their price objective on shares of Boston Scientific from $90.00 to $85.00 and set a “buy” rating on the stock in a report on Tuesday, April 21st. Jefferies Financial Group reduced their price objective on shares of Boston Scientific from $110.00 to $100.00 and set a “buy” rating on the stock in a report on Wednesday, April 22nd. JPMorgan Chase & Co. reduced their price objective on shares of Boston Scientific from $135.00 to $100.00 and set an “overweight” rating on the stock in a report on Thursday, February 5th. Finally, Argus upgraded shares of Boston Scientific to a “strong-buy” rating in a report on Thursday, February 26th. One analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, Boston Scientific presently has an average rating of “Moderate Buy” and an average target price of $93.91.

Boston Scientific Stock Performance

NYSE BSX opened at $56.96 on Tuesday. The company has a market cap of $84.66 billion, a P/E ratio of 23.83, a P/E/G ratio of 1.04 and a beta of 0.62. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.62 and a quick ratio of 1.08. The stock has a 50-day moving average of $67.06 and a two-hundred day moving average of $84.57. Boston Scientific Corporation has a 1-year low of $56.05 and a 1-year high of $109.50.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings data on Wednesday, April 22nd. The medical equipment provider reported $0.80 EPS for the quarter, topping analysts’ consensus estimates of $0.79 by $0.01. Boston Scientific had a return on equity of 19.68% and a net margin of 17.29%.The business had revenue of $5.20 billion during the quarter, compared to the consensus estimate of $5.19 billion. During the same period in the previous year, the company posted $0.75 earnings per share. The business’s revenue for the quarter was up 11.6% on a year-over-year basis. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. As a group, analysts anticipate that Boston Scientific Corporation will post 3.38 EPS for the current year.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.